Video-urodynamic Improvement of Trigonal BTX-A Injection for Patients with Poor Bladder Compliance Secondary to Spinal Cord Injury

Jiang Zhuocheng¹, Chen Hui^{2, 3,} , Yang XH², Huang MP², Huang TH², Liu QL², Li QQ², Yang XY², Xiao XH², Liu J², Xie Keji⁴ and Jiang Chonghe³

¹Department of Surgery, The Second People's Hospital of Baiyun District, Guangzhou, China

²Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital and Jinan University, Guangzhou, China

³Department of Urology, Qingyan City People's Hospital, Jinan University, Guangdong, China

⁴Department of Urology, Guangzhou First Municipal People’s Hospital, Guangzhou, China

Cite this paper:
Jiang Zhuocheng, Chen Hui, Yang XH, Huang MP, Huang TH, Liu QL, Li QQ, Yang XY, Xiao XH, Liu J, Xie Keji and Jiang Chonghe. Video-urodynamic Improvement of Trigonal BTX-A Injection for Patients with Poor Bladder Compliance Secondary to Spinal Cord Injury. American Journal of Medical Case Reports. 2018; 6(1):15-17. doi: 10.12691/ajmcr-6-1-5

Abstract

Objective: To evaluate video-urodynamic improvement for trigonal BTX-A injection in patients with neurological poor bladder compliance. Methods: 68 consecutive inpatients with poor bladder compliance secondary to spinal cord injury(SCI) received trigonal injections of BTX-A(300U) into the bladder from June 2014 to February 2017. All were evaluated video-urodynamic outcome included detrusor leak point pressure (DLPP), bladder compliance (BC) and vesicoureteral reflux (VUR) at baseline and 12 weeks post-injection. Results: all outcomes improved significantly compared to baseline. The improvement percentage of DLPP (44.36%) and BC(77.13%). No patient developed unilateral or bilateral VUR. Conclusions: Trigone-including BTX-A injection is safe and effective as the treatment for low BC and does not induce VUR.

Keywords:
video-urodynamic bladder trigone botulinum toxin A low bladder compliance spinal cord injury

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Stöhrer M, Goepel M, Kondo A, et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn. 1999; 18(2): 139-158.
[2]	Gerridzen RG, Thijssen AM, Dehoux E, et al. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J Urol, 1992. 147(2): 416-8.
[3]	Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol, 2009, 56(1): 81-88.
[4]	Marte A. Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele. Toxins 2013; 5(1): 16-24.
[5]	Schurch B, de Sèze M, Denys P,et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol, 2005. 174(1): 196-200.
[6]	Huang M, Chen H, Jiang C, et al. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J RehabilMed. 2016; 48(8): 683-687.
[7]	Citeri M, Spinelli M, Zanollo L, et al. Botulinum toxin into the trigone in neurogenic overactive bladder non-responder to detrusor injection. Eur Urol Suppl 2008; 7: 213.
[8]	Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxin A for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011; 30: 1242-1248.
[9]	Pinto R, Lopes T, Frias B, Silva JA, Silva CM, Cruz C et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-365.
[10]	Hui C, Keji X, Chonghe J, et al. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord. 2016; 54(1): 46-50.
[11]	Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxin A for refractory idiopathic detrusor overactivity. Eur Urol 2012; 61: 928–935.
[12]	Conte A, Giannantoni A, Gubbiotti M, et al. Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study. Toxins.2015; 7(9): 3424-3435.
[13]	Patrick DL, Martin ML, Bushnell DM, et al. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instru ment (I-QOL). Urology19 99; 53:71-76.
[14]	Del Popolo G. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol, 2008. 53(5): p. 1013-19.
[15]	Cruz F. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol, 2011. 60(4): p. 742-50.
[16]	Ginsberg D. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol, 2012. 187(6): p. 2131-9.
[17]	Grosse J. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol, 2005. 47(5): p.653-9.
[18]	Stöhrer M. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. Eur Urol Update Series 1994. 3: p. 170-5.
[19]	Castro-Diaz D. Surgery for the neuropathic patient. In Incontinence, P. Abrams, et al., Editors. 2002, Health Publication: Plymouth. p. 865-891.
[20]	Frankel HL. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord, 1998. 36(4): p. 266-74.
[21]	Jamil F. Towards a catheter free status in neurogenic bladder dysfunction: a review of bladder management options in spinal cord injury (SCI). Spinal Cord, 2001. 39(7): p. 355-61.
[22]	Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol, 2000, 164 ( 1):692-697.
[23]	Cohen BL, Barboglio P, Rodriguez D, et al. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009; 28 ( 1): 205-8.
[24]	Klein LA. Urge incontinence can be a disease of bladder sensors. J Urol 1988; 139(5): 1010-1014.